Research Corporation Technologies played an early role in the commercial success of some of today's important pharmaceuticals, diagnostics, biotechnology products, new materials and processes. Some of these include:
Cisplatin and Carboplatin Anticancer Drugs
These anticancer agents are mainstays of the chemotherapy armamentarium for treatment of testicular, ovarian, lung and other cancers. In 2003, Bristol-Myers Squibb's Paraplatin™ earned worldwide sales of more than $900 million.
The PSA Blood Test for Prostate Cancer
The test, now part of routine prostate cancer screening for most men over 50, is the only FDA-approved blood-based screening test for any cancer.
Technetium-99-based Imaging Agents
Technetium-99 is one of the most common radionuclides used today in cardiac imaging, and is also employed in bone, breast and liver imaging.
The Pichia Yeast Protein Expression System
The number of companies licensed to use the Pichia system exceeds 120 and is growing. The system was the first in an array of the most widely used gene expression systems, tools and genes now available through RCT's convenient and affordable Gene eXpression Technologies licensing program.
The Blue Noise Mask Halftoning Technology
Several of the world's printing industry leaders made the patented technology an integral part of many of their products.
Granulocyte-Macrophage Colony Stimulating Factor
Two international pharmaceutical companies make recombinant versions of the factor, which is in use worldwide to bolster the immune systems of cancer chemotherapy patients, AIDS patients and persons with rare white-blood-cell diseases.
Silver Sulfadiazine Burn Ointment
First employed on a large scale during the Vietnam War, silver sulfadiazine remains the major antibiotic for burn patients.
Fullerenes
RCT, the giant trading company, Mitsubishi Corporation, and Materials and Electrochemical Research Corporation are partners in a joint venture to commercialize fullerene materials.
Non-Immunogenic Delivery of Protein-Based Drugs
Enzon Pharmaceuticals developed several advanced treatments for life-threatening illnesses, most notably a therapy for children who lack immune systems and another for childhood leukemia.
We are proud of our contribution to the success of these products and are committed to developing and financing the next generation of innovative technologies.